Astrazeneca plc
NASDAQ: AZN
$63.85
-$2.42 (-3.7%)
Closing Price on November 6, 2024
AZN Articles
The FDA is routinely criticized for being a poor steward of drug research and pharmaceutical side effects. The agency proved once again why much of the criticism is justified. The FDA today said...
Published:
Last Updated:
These are Thursday’s top ten analyst research summary upgrades, downgrades, and initiations from Wall Street brokerage firms: AstraZeneca (AZN) Cut to Hold at Citigroup. Brandywine Realty (BDN) Cut...
Published:
Diabetes is becoming an epidemic in the U.S. and the Western World. The ties to obesity are often direct, so the potential treatments are often directly tied as well. We did a recent dig down for...
Published:
Last Updated:
You can just see the TV advertisements now… Wal-Mart and Uncle Sam are “rolling back” swine flu. The retailer is in talks with federal officials about possibly putting vaccination sites in its...
Published:
Last Updated:
Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market....
Published:
Last Updated:
Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early afternoon Thursday after Japan okayed one of the company’s human growth hormones, the first approval...
Published:
These are the top 10 early bird analyst upgrades and downgrades we have seen in Wall Street research calls early this Thursday morning with over two hours until the market opens: AstraZeneca (AZN)...
Published:
These are some of the top pre-market analyst upgrades we have seen from Wall Street early this Monday morning: AstraZeneca (AZN) Raised to Buy at UBS. BioMed Realty Trust (BMR) Raised to Outperform...
Published:
This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks. The American Association for Cancer Research Meeting will actually have a 100th annual...
Published:
These are some of the many pre-market downgrades and negative calls we have seen from Wall Street analysts this Friday morning:Allstate (ALL) Cut to Underweight at JPMorgan.AstraZeneca (AZN) Cut to...
Published:
These are some of the top pre-market analyst upgrades and positive calls we have seen on Wall Street this Friday morning: Accuray (ARAY) Raised to Buy at Piper Jaffray. AstraZeneca (AZN) Raised to...
Published:
We have run a full feature story over at BioHealthInvestor.com after reading a study that came off the Mayo Clinic site. The study showed that a combination of fish oil and red rice yeast in...
Published:
Last night was a novel release from the American Society of Clinical Oncology (or ASCO) as the society decided to publish all of the findings to the public at once. Keep in mind that many of the...
Published:
Last Updated:
These aren’t the only impact analyst calls this morning, but these are the ones we are focusing the Tuesday in pre-market trading hours: Akamai Tech (NASDAQ: AKAM) Raised to Buy from Neutral at...
Published:
Below are the ten analyst calls that a673b.bigscoots-temp.com is focusing on in pre-market trading this Wednesday morning: AstraZeneca (NYSE: AZN) raised to Overweight at HSBC Securities. Bunge (NYSE: BG)...
Published: